With a high prevalence of newly diagnosed DM patients at the time of an ACS event and a high rate of insulin refusal, especially in treatment‐naïve patients, our results provide evidence for a safe and effective alternative treatment strategy for DM management based on data from real‐life experience. The gene discussed is INS; the disease is diabetes mellitus.